Debasish Sundi, MD
Academic Title: Assistant Professor in the College of Medicine
Research Program: Cancer Biology
About Me
More info forI am a urologic oncology specialist providing medical and surgical care to patients with bladder and urothelial cancers. I became a physician-scientist because I am passionate about using advancements from the lab to improve patient care, and I participate in the conduct, analysis, and initiation of bladder cancer clinical trials to advance that goal. As an assistant professor of Urology and a member of the Cancer Control Program at the OSUCCC – James, my research centers on exploring the functions of immune cells in the bladder cancer tumor microenvironment. In my bladder cancer immunology research laboratory, my team and I are currently focused on how biological sex differences influence the body’s natural immune responses. We are also exploring how modulating androgen signaling in bladder tumors may improve immune responses against cancer. I have been honored to receive awards to further my research, including the Physician Scientist Retention in Research Award from the Doris Duke Charitable Foundation, the Research Scholar Award from the Urology Care Foundation, and a Department of Defense Career Development Award. I have co-authored multiple articles published in peer-reviewed journals. I also currently serve on panels at the National Comprehensive Cancer Network focused on setting recommended treatment guidelines for bladder and penile cancers.
Clinical Expertise
More info for- Bladder Cancer
- Kidney Cancers
- Testicular Cancers
- Urology
- Prostate Cancers
- Adrenal Gland Cancers
- Urethral Cancers
- Hematuria
- Minimally Invasive Surgical Procedures
- Robotics
- Urogenital Cancers
Research Interests
More info for- Translational Research, Biomedical
- Carcinogenesis
- Single-Cell Analysis
- Cell Culture Techniques
- Urinary Bladder Neoplasms
- Tumor Microenvironment
- Myeloid Cells
- Biomarkers
- T-Lymphocytes
- Surgical Oncology
Where I See Patients
More info forEducation & Training
More info forInternship - Surgery (General Surgery)
- Johns Hopkins Hospital
600 N Wolfe St, Baltimore, MD
Residency - Urology
- Johns Hopkins Hospital
600 N Wolfe St, Baltimore, MD
Medical School
- Northwestern University Feinberg School of Medicine
420 E Superior St, Chicago, IL
Fellowship - Urologic Oncology
- University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd, Houston, TX
- Johns Hopkins Hospital
Academic Office & Contact Information
More info forAcademic Office:
Tzagournis Medical Research Fa 0690A
420 W 12th Ave
Columbus, Ohio 43210-2208Email:
sundi.1@osu.eduVideos
More info forPublications
More info forOctober 2, 2024A Slow March Toward Eliminating Transfusion in Uro-Oncology.
Dason S, Sundi D, Sood A
JAMA Surg
May 1, 2024Bladder Cancer, Version 3.2024.
Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK, Chan K, Chang SS, Chang P, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kaimakliotis H, Kishan AU, Kundu S, Lele SM, Mamtani R, Mian OY, Michalski J, Montgomery JS, Parikh M, Patterson A, Peyton C, Plimack ER, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Stewart T, Sundi D, Tollefson M, Tward J, Wright JL, Cassara CJ, Gurski LA
J Natl Compr Canc Netw
April 26, 2024Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions.
Purdue MP, Dutta D, Machiela MJ, Gorman BR, Winter T, Okuhara D, Cleland S, Ferreiro-Iglesias A, Scheet P, Liu A, Wu C, Antwi SO, Larkin J, Zequi SC, Sun M, Hikino K, Hajiran A, Lawson KA, Cárcano F, Blanchet O, Shuch B, Nepple KG, Margue G, Sundi D, Diver WR, Folgueira MAAK, van Bokhoven A, Neffa F, Brown KM, Hofmann JN, Rhee J, Yeager M, Cole NR, Hicks BD, Manning MR, Hutchinson AA, Rothman N, Huang WY, Linehan WM, Lori A, Ferragu M, Zidane-Marinnes M, Serrano SV, Magnabosco WJ, BioBank Japan Project , Vilas A, Decia R, Carusso F, Graham LS, Anderson K, Bilen MA, Arciero C, Pellegrin I, Ricard S, FinnGen , Scelo G, Banks RE, Vasudev NS, Soomro N, Stewart GD, Adeyoju A, Bromage S, Hrouda D, Gibbons N, Patel P, Sullivan M, Protheroe A, Nugent FI, Fournier MJ, Zhang X, Martin LJ, Komisarenko M, Eisen T, Cunningham SA, Connolly DC, Uzzo RG, Zaridze D, Mukeria A, Holcatova I, Hornakova A, Foretova L, Janout V, Mates D, Jinga V, Rascu S, Mijuskovic M, Savic S, Milosavljevic S, Gaborieau V, Abedi-Ardekani B, McKay J, Johansson M, Phouthavongsy L, Hayman L, Li J, Lungu I, Bezerra SM, Souza AG, Sares CTG, Reis RB, Gallucci FP, Cordeiro MD, Pomerantz M, Lee GM, Freedman ML, Jeong A, Greenberg SE, Sanchez A, Thompson RH, Sharma V, Thiel DD, Ball CT, Abreu D, Lam ET, Nahas WC, Master VA, Patel AV, Bernhard JC, Freedman ND, Bigot P, Reis RM, Colli LM, Finelli A, Manley BJ, Terao C, Choueiri TK, Carraro DM, Houlston R, Eckel-Passow JE, Abbosh PH, Ganna A, Brennan P, Gu J, Chanock SJ
Nat Genet
February 10, 2024Roles of Androgen Receptor Signaling in Urothelial Carcinoma.
Sundi D, Collier KA, Yang Y, Diaz DA, Pohar KS, Singer EA, Gupta S, Carson WE, Clinton SK, Li Z, Messing EM
Cancers (Basel)
January 12, 2024A Comprehensive Review of Immunotherapy Clinical Trials for Metastatic Urothelial Carcinoma: Immune Checkpoint Inhibitors Alone or in Combination, Novel Antibodies, Cellular Therapies, and Vaccines.
Patel DM, Mateen R, Qaddour N, Carrillo A, Verschraegen C, Yang Y, Li Z, Sundi D, Mortazavi A, Collier KA
Cancers (Basel)
January 5, 2024Melanoma Antigen Family A (MAGE A) as Promising Biomarkers and Therapeutic Targets in Bladder Cancer.
Verma S, Swain D, Kushwaha PP, Brahmbhatt S, Gupta K, Sundi D, Gupta S
Cancers (Basel)
January 1, 2024Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle Invasive Bladder Cancer.
McConkey DJ, Baumann BC, Cooper Greenberg S, DeGraff DJ, Delacroix SE, Efstathiou JA, Foster J, Groshen S, Kadel EE, Khani F, Kim WY, Lerner SP, Levin T, Liao JC, Milowsky MI, Meeks JJ, Miyamoto DT, Mouw KW, Pietzak EJ, Solit DB, Sundi D, Tawab-Amiri A, West PJ, Wobker SE, Wyatt AW, Apolo AB, Black PC
Bladder Cancer
December 27, 2023PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy.
Grivas P, Koshkin VS, Chu X, Cole S, Jain RK, Dreicer R, Cetnar JP, Sundi D, Gartrell BA, Galsky MD, Woo B, Li-Ning-Tapia E, Hahn NM, Carducci MA
Eur Urol Oncol
April 13, 2023Heterogeneity of BCG unresponsive bladder cancer clinical trials limits patients' access to novel therapeutics.
Chandra M, Li R, Parwani A, Carson WE, Pohar K, Sundi D
Urol Oncol
August 19, 2022Sex-biased adaptive immune regulation in cancer development and therapy.
Schafer JM, Xiao T, Kwon H, Collier K, Chang Y, Abdel-Hafiz H, Bolyard C, Chung D, Yang Y, Sundi D, Ma Q, Theodorescu D, Li X, Li Z
iScience
April 14, 2022Androgen conspires with the CD8+ T cell exhaustion program and contributes to sex bias in cancer.
Kwon H, Schafer JM, Song NJ, Kaneko S, Li A, Xiao T, Ma A, Allen C, Das K, Zhou L, Riesenberg B, Chang Y, Weltge P, Velegraki M, Oh DY, Fong L, Ma Q, Sundi D, Chung D, Li X, Li Z
Sci Immunol
March 15, 2021Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomy.
Wilkins LJ, Tosoian JJ, Reichard CA, Sundi D, Ranasinghe W, Alam R, Schwen Z, Reddy C, Allaf M, Davis JW, Chapin BF, Ross AE, Klein EA, Nyame YA
Cancer
March 10, 2021Robotic Radical Cystectomy, Pelvic Lymph Node Dissection, and Intracorporeal Ileal Conduit Urinary Diversion.
Stillings SA, Sundi D
J Vis Exp
January 9, 2021Neoadjuvant chemotherapy in bladder cancer: Clinical benefit observed in prospective trials computed with restricted mean survival times.
McCaw ZR, Odisho AY, Chaparala H, Yin M, Cloyd J, Svatek RS, Carson WE, Lee CT, Sundi D
Urol Oncol
November 10, 2020Surgical management of high-risk, localized prostate cancer.
Wilkins LJ, Tosoian JJ, Sundi D, Ross AE, Grimberg D, Klein EA, Chapin BF, Nyame YA
Nat Rev Urol
April 7, 2020Downgrading from Biopsy Grade Group 4 Prostate Cancer in Patients Undergoing Radical Prostatectomy for High or Very High Risk Prostate Cancer.
Ranasinghe W, Reichard CA, Nyame YA, Sundi D, Tosoian JJ, Wilkins L, Alam R, Achim MF, Wang X, Stephenson AJ, Klein EA, Ross AE, Allaf ME, Davis JW, Chapin BF
J Urol
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Sundi has reported no relationships with companies or entities.